Shahram Attarian

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5846985/publications.pdf

Version: 2024-02-01

139 papers	7,500 citations	101496 36 h-index	62565 80 g-index

152 all docs	152 docs citations	152 times ranked	8246 citing authors

#	Article	IF	Citations
1	Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 11-21.	13.9	1,944
2	Phenotypic Study in 40 Patients With Dysferlin Gene Mutations. Archives of Neurology, 2007, 64, 1176.	4.9	230
3	Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2021, 20, 526-536.	4.9	194
4	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2018, 17, 35-46.	4.9	193
5	Regional variation of Guillain-BarrÃ© syndrome. Brain, 2018, 141, 2866-2877.	3.7	190
6	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Forceâ€”Second revision. Journal of the Peripheral Nervous System, 2021, 26, 242-268.	1.4	176
7	MUSK, a new target for mutations causing congenital myasthenic syndrome. Human Molecular Genetics, 2004, 13, 3229-3240.	1.4	175
8	Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin. Archives of Neurology, 2005, 62, 1689.	4.9	169
9	Constitutive Activation of the Calcium Sensor STIM1 Causes Tubular-Aggregate Myopathy. American Journal of Human Genetics, 2013, 92, 271-278.	2.6	169
10	Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain, 2017, 140, 1851-1858.	3.7	167
11	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Forceâ€”Second revision. European Journal of Neurology, 2021, 28, 3556-3583.	1.7	153
12	Effect of ascorbic acid in patients with Charcotâ€“Marieâ€“Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2009, 8, 1103-1110.	4.9	114
13	Multifocal motor neuropathy with and without conduction block: A single entity?. Neurology, 2006, 67, 592-596.	1.5	112
14	Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers ofTTRgene mutations*. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 3-9.	1.4	102
15	Development of a French Isometric Strength Normative Database for Adults Using Quantitative Muscle Testing. Archives of Physical Medicine and Rehabilitation, 2007, 88, 1289-1297.	0.5	97
16	Analysis of theDYSFmutational spectrum in a large cohort of patients. Human Mutation, 2009, 30, E345-E375.	1.1	97
17	An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet Journal of Rare Diseases, 2014, 9, 199.	1.2	94
18	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	4.9	93

#	Article	IF	Citations
19	Lewis-Sumner syndrome and multifocal motor neuropathy. Muscle and Nerve, 2005, 31, 88-94.	1.0	84
20	Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies. Clinical Neurophysiology, 2001, 112, 457-463.	0.7	78
21	Deregulation of the Protocadherin Gene FAT1 Alters Muscle Shapes: Implications for the Pathogenesis of Facioscapulohumeral Dystrophy. PLoS Genetics, 2013, 9, e1003550.	1.5	73
22	Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Revue Neurologique, 2020, 176, 507-515.	0.6	71
23	ALS with respiratory onset: Clinical features and effects of non-invasive ventilation on the prognosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 379-382.	2.3	66
24	Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. Journal of Neurology, 2020, 267, 3664-3672.	1.8	63
25	Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1051-1060.	0.9	53
26	Transcranial magnetic stimulation in lower motor neuron diseases. Clinical Neurophysiology, 2005, 116, 35-42.	0.7	50
27	Neurologic Disorders and Hepatitis E, France, 2010. Emerging Infectious Diseases, 2011, 17, 1510-2.	2.0	50
28	Novel Electromyographic Monitoring Technique for Prevention of Right Phrenic Nerve Palsy During Cryoballoon Ablation. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 1109-1114.	2.1	50
29	Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. Journal of Neuroinflammation, 2017, 14, 224.	3.1	50
30	Microinfusion of the Metabotropic Glutamate Receptor Agonist 1S, 3R-1-Aminocyclopentane-1, 3-dicarboxylic Acid Into the Nucleus Accumbens Induces Dopamine-dependent Locomotor Activation in the Rat. European Journal of Neuroscience, 1997, 9, 809-816.	1.2	49
31	Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 61-64.	0.9	49
32	Dysregulation of 4q35- and muscle-specific genes in fetuses with a short D4Z4 array linked to facio-scapulo-humeral dystrophy. Human Molecular Genetics, 2013, 22, 4206-4214.	1.4	45
33	Molecular combing reveals allelic combinations in facioscapulohumeral dystrophy. Annals of Neurology, 2011, 70, 627-633.	2.8	44
34	Response to treatment in patients with lewisâ€“sumner syndrome. Muscle and Nerve, 2011, 44, 179-184.	1.0	41
35	Magnetic stimulation using a triple-stimulation technique in patients with multifocal neuropathy without conduction block. Muscle and Nerve, 2005, 32, 710-714.	1.0	40
36	Muscle Quantitative MR Imaging and Clustering Analysis in Patients with Facioscapulohumeral Muscular Dystrophy Type 1. PLoS ONE, 2015, 10, e0132717.	1.1	40

#	Article	IF	Citations
37	Assessment of cortico-spinal tract impairment in multiple system atrophy using transcranial magnetic stimulation. Clinical Neurophysiology, 2007, 118, 815-823.	0.7	39
38	Internal modeling of upcoming speech: A causal role of the right posterior cerebellum in non-motor aspects of language production. Cortex, 2016, 81, 203-214.	1.1	39
39	SMCHD1 is involved inde novomethylation of theDUX4-encoding D4Z4 macrosatellite. Nucleic Acids Research, 2019, 47, 2822-2839.	6.5	39
40	Measuring Outcomes in Adults with Spinal Muscular Atrophy â€“ Challenges and Future Directions â€“ Meeting Report. Journal of Neuromuscular Diseases, 2020, 7, 523-534.	1.1	39
41	Molecular combing reveals complex 4q35 rearrangements in Facioscapulohumeral dystrophy. Human Mutation, 2017, 38, 1432-1441.	1.1	39
42	Identification of Variants in the 4q35 GeneFAT1in Patients with a Facioscapulohumeral Dystrophy-Like Phenotype. Human Mutation, 2015, 36, 443-453.	1.1	38
43	Myofibrillar myopathies: State of the art, present and future challenges. Revue Neurologique, 2015, 171, 715-729.	0.6	38
44	Multiple acyl-CoA dehydrogenase deficiency (MADD) as a cause of late-onset treatable metabolic disease. Revue Neurologique, 2016, 172, 231-241.	0.6	38
45	Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis. Neurology, 2021, 96, e2109-e2120.	1.5	38
46	Triple-stimulation technique in multifocal neuropathy with conduction block. Muscle and Nerve, 2007, 35, 632-636.	1.0	37
47	Regionâ€specific impairment of the cervical spinal cord (SC) in amyotrophic lateral sclerosis: A preliminary study using SC templates and quantitative MRI (diffusion tensor imaging/inhomogeneous) Tj ETQq1 1 0.784314 rgBT /Ov	1.4	37
48	Transcranial magnetic stimulation (TMS): compared sensitivity of different motor response parameters in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2000, 1, 45-49.	1.4	37
49	Molecular diagnosis of inherited peripheral neuropathies by targeted next-generation sequencing: molecular spectrum delineation. BMJ Open, 2018, 8, e021632.	0.8	36
50	Magnetic stimulation including the triple-stimulation technique in amyotrophic lateral sclerosis. Muscle and Nerve, 2007, 36, 55-61.	1.0	35
51	Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins. Clinical Neurophysiology, 2020, 131, 921-927.	0.7	34
52	Long-term follow-up of MRI changes in thigh muscles of patients with Facioscapulohumeral dystrophy: A quantitative study. PLoS ONE, 2017, 12, e0183825.	1.1	33
53	Periodic Salbutamol in Facioscapulohumeral Muscular Dystrophy: A Randomized Controlled Trial. Archives of Physical Medicine and Rehabilitation, 2009, 90, 1094-1101.	0.5	32
54	Low penetrance in facioscapulohumeral muscular dystrophy type 1 with large pathological D4Z4 alleles: a cross-sectional multicenter study. Orphanet Journal of Rare Diseases, 2015, 10, 2.	1.2	32

#	Article	IF	Citations
55	Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy. Journal of the Neurological Sciences, 2017, 377, 144-148.	0.3	32
56	Enteral and parenteral nutrition in the later stages of ALS: An observational study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 42-46.	2.3	31
57	Expanding the importance of HMERF titinopathy: new mutations and clinical aspects. Journal of Neurology, 2019, 266, 680-690.	1.8	31
58	Hereditary neuropathy with liability to pressure palsies. Journal of Neurology, 2020, 267, 2198-2206.	1.8	31
59	Primary neurolymphomatosis diagnosis and treatment: A retrospective study. Journal of the Neurological Sciences, 2014, 342, 178-181.	0.3	30
60	Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review. Muscle and Nerve, 2018, 57, 875-883.	1.0	30
61	The utility of motor unit number index: A systematic review. Neurophysiologie Clinique, 2018, 48, 251-259.	1.0	30
62	Guillainâ€BarrÃ‰ syndrome subtype diagnosis: A prospective multicentric European study. Muscle and Nerve, 2018, 58, 23-28.	1.0	29
63	Progression of cortical and spinal dysfunctions over time in amyotrophic lateral sclerosis. Muscle and Nerve, 2008, 37, 364-375.	1.0	27
64	A motor cortex excitability and gait analysis on Parkinsonian patients. Movement Disorders, 2010, 25, 2747-2755.	2.2	27
65	Association between structural and functional corticospinal involvement in amyotrophic lateral sclerosis assessed by diffusion tensor MRI and triple stimulation technique. Muscle and Nerve, 2014, 49, 551-557.	1.0	27
66	Quantitative multiplex PCR of short fluorescent fragments for the detection of large intragenic POLG rearrangements in a large French cohort. European Journal of Human Genetics, 2014, 22, 542-550.	1.4	27
67	Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS. Scientific Reports, 2021, 11, 703.	1.6	27
68	Clinical features and followâ€up of four new cases of facialâ€onset sensory and motor neuronopathy. Muscle and Nerve, 2011, 43, 136-140.	1.0	26
69	Motor unit number index (MUNIX): Is it relevant in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)?. Clinical Neurophysiology, 2016, 127, 1891-1894.	0.7	25
70	New strategy for improving the diagnostic sensitivity of repetitive nerve stimulation in myasthenia gravis. Muscle and Nerve, 2017, 55, 532-538.	1.0	25
71	Upper limb onset of hereditary transthyretin amyloidosis is common in nonâ€endemic areas. European Journal of Neurology, 2019, 26, 497.	1.7	25
72	Prospective clinical and electrophysiological follow-up on a multiple sclerosis population treated with interferon beta-1 a. Multiple Sclerosis Journal, 2007, 13, 348-356.	1.4	24

#	Article	IF	Citations
73	Acute motor and sensory axonal neuropathy and concomitant encephalopathy during tumor necrosis factor-alpha antagonist therapy. Journal of the Neurological Sciences, 2010, 291, 103-106.	0.3	24
74	Quantitative Brain Sodium MRI Depicts Corticospinal Impairment in Amyotrophic Lateral Sclerosis. Radiology, 2019, 292, 422-428.	3.6	24
75	Deciphering the complexity of the 4q and 10q subtelomeres by molecular combing in healthy individuals and patients with facioscapulohumeral dystrophy. Journal of Medical Genetics, 2019, 56, 590-601.	1.5	24
76	Characteristics of patients with vitamin B12-responsive neuropathy: a case series with systematic repeated electrophysiological assessment. Neurological Research, 2019, 41, 569-576.	0.6	24
77	Cortical versus spinal dysfunction in amyotrophic lateral sclerosis. Muscle and Nerve, 2006, 33, 677-690.	1.0	23
78	A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcotâ€“Marieâ€“Tooth type 1A. Orphanet Journal of Rare Diseases, 2021, 16, 433.	1.2	23
79	Motor evoked potentials in clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 355-362.	1.4	22
80	Clinical spectrum and gender differences in a large cohort of Charcotâ€“Marieâ€“Tooth type 1A patients. Journal of the Neurological Sciences, 2014, 336, 155-160.	0.3	22
81	Global motor unit number index sum score for assessing the loss of lower motor neurons in amyotrophic lateral sclerosis. Muscle and Nerve, 2017, 56, 202-206.	1.0	22
82	Charcotâ€“Marieâ€“Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: An international multicentric retrospective study. European Journal of Neurology, 2021, 28, 2846-2854.	1.7	22
83	Predicting Outcome in Guillain-BarrÃ© Syndrome. Neurology, 2022, 98, .	1.5	22
84	Rapid identification of mitochondrial DNA (mtDNA) mutations in neuromuscular disorders by using surveyor strategy. Mitochondrion, 2008, 8, 136-145.	1.6	21
85	Novel CAPN3 variant associated with an autosomal dominant calpainopathy. Neuropathology and Applied Neurobiology, 2020, 46, 564-578.	1.8	20
86	Excitability of the lower-limb area of the motor cortex in Parkinson's disease. Neurophysiologie Clinique, 2010, 40, 201-208.	1.0	19
87	Recommendations for the management of facioscapulohumeral muscular dystrophy in 2011. Revue Neurologique, 2012, 168, 910-918.	0.6	19
88	Motor unit number index correlates with disability in Charcot-Marie-Tooth disease. Clinical Neurophysiology, 2018, 129, 1390-1396.	0.7	19
89	Management challenges for chronic dysimmune neuropathies during the <scp>COVID</scp>â€19 pandemic. Muscle and Nerve, 2020, 62, 34-40.	1.0	19
90	Neonatal lower motor neuron syndrome associated with maternal neuropathy with anti-GM1 IgG. Neurology, 2004, 63, 379-381.	1.5	18

#	Article	IF	Citations
91	Tripleâ€stimulation technique improves the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. Muscle and Nerve, 2015, 51, 541-548.	1.0	18
92	Quantitative muscle MRI study of patients with sporadic inclusion body myositis. Muscle and Nerve, 2020, 61, 496-503.	1.0	18
93	Fat fraction distribution in lower limb muscles of patients with CMT1A. Neurology, 2020, 94, e1480-e1487.	1.5	18
94	Muscle MRI of facioscapulohumeral dystrophy (FSHD): A growing demand and a promising approach. Revue Neurologique, 2016, 172, 566-571.	0.6	17
95	Determinants of healthâ€related quality of life in antiâ€‹scp›MAG‹/scp› neuropathy: a crossâ€sectional multicentre European study. Journal of the Peripheral Nervous System, 2017, 22, 27-33.	1.4	17
96	Selective inhibition of antiâ€MAG IgM autoantibody binding to myelin by an antigenâ€specific glycopolymer. Journal of Neurochemistry, 2020, 154, 486-501.	2.1	17
97	Monitoring the short-term effect of intravenous immunoglobulins in multifocal motor neuropathy using motor unit number index. Clinical Neurophysiology, 2017, 128, 235-240.	0.7	16
98	Changes in cortically induced inhibition in amyotrophic lateral sclerosis with time. Muscle and Nerve, 2009, 39, 310-317.	1.0	15
99	Paraneoplastic subacute lower motor neuron syndrome associated with solid cancer. Journal of the Neurological Sciences, 2015, 358, 413-416.	0.3	15
100	Motor unit number index (MUNIX) in patients with anti-MAG neuropathy. Clinical Neurophysiology, 2017, 128, 1264-1269.	0.7	15
101	Detection of proximal conduction blocks using a triple stimulation technique improves the early diagnosis of Guillainâ€“BarrÃ© syndrome. Clinical Neurophysiology, 2018, 129, 127-132.	0.7	15
102	Fibromyalgiaâ€like symptoms associated with irritable bowel syndrome: A challenging diagnosis of lateâ€onset Pompe disease. Muscle and Nerve, 2015, 52, 300-304.	1.0	14
103	Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies. Journal of Neurology, 2019, 266, 1973-1979.	1.8	14
104	Wish to die and reasons for living among patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 68-73.	1.1	14
105	Expanding the spectrum of VEXAS syndrome: association with acute-onset CIDP. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 797-798.	0.9	14
106	A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment. Orphanet Journal of Rare Diseases, 2015, 10, 74.	1.2	13
107	Dysferlinopathy in Iran: Clinical and genetic report. Journal of the Neurological Sciences, 2015, 359, 256-259.	0.3	12
108	Motor cortical reorganization is present after a single attack of multiple sclerosis devoid of cortico-spinal dysfunction. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2011, 24, 77-84.	1.1	11

#	Article	IF	Citations
109	Motor unit number index as an individual biomarker: Reference limits of intra-individual variability over time in healthy subjects. Clinical Neurophysiology, 2020, 131, 2209-2215.	0.7	11
110	Immunoglobulin shortage: Practice modifications and clinical outcomes in a reference centre. Revue Neurologique, 2022, 178, 616-623.	0.6	11
111	Covariation of corticospinal efficiency and silent period in motoneuron diseases. Muscle and Nerve, 2006, 34, 178-188.	1.0	10
112	A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases. Orphanet Journal of Rare Diseases, 2021, 16, 450.	1.2	9
113	Quantitative sudomotor test helps differentiate transthyretin familial amyloid polyneuropathy from chronic inflammatory demyelinating polyneuropathy. Clinical Neurophysiology, 2020, 131, 1129-1133.	0.7	8
114	Prevalence of spasticity and spasticity-related pain among patients with Amyotrophic Lateral Sclerosis. Revue Neurologique, 2021, 177, 694-698.	0.6	8
115	Enhancement of single motor unit inhibitory responses to transcranial magnetic stimulation in amyotrophic lateral sclerosis. Experimental Brain Research, 2008, 189, 229-242.	0.7	7
116	Proximal conduction block in the pharyngealâ€“cervicalâ€“brachial variant of guillainâ€“barrÃ‰ syndrome. Muscle and Nerve, 2015, 52, 1102-1106.	1.0	7
117	Disorders of motor neurons manifested by hyperactivity. Revue Neurologique, 2017, 173, 345-351.	0.6	7
118	Alterations of Microstructure and Sodium Homeostasis in Fast Amyotrophic Lateral Sclerosis Progressors: A Brain DTI and Sodium MRI Study. American Journal of Neuroradiology, 2022, 43, 984-990.	1.2	7
119	Quantitative assessment of sciatic nerve changes in Charcotâ€“Marieâ€“Tooth type 1A patients using magnetic resonance neurography. European Journal of Neurology, 2020, 27, 1382-1389.	1.7	6
120	Genotypeâ€“phenotype correlation in French patients with myelin protein zero geneâ€related inherited neuropathy. European Journal of Neurology, 2021, 28, 2913-2921.	1.7	6
121	Motor-evoked potential gain is a helpful test for the detection of corticospinal tract dysfunction in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2017, 128, 357-364.	0.7	5
122	Guillainâ€“BarrÃ© syndrome subtypes: A clinical electrophysiological study of 100 patients. Revue Neurologique, 2019, 175, 73-80.	0.6	5
123	Evolving Immunologic Perspectives in Chronic Inflammatory Demyelinating Polyneuropathy . Journal of Inflammation Research, 2020, Volume 13, 543-549.	1.6	5
124	Motor unit number index: A potential electrophysiological biomarker for pediatric spinal muscular atrophy. Muscle and Nerve, 2021, 64, 445-453.	1.0	5
125	Shoulder palsy following SARSâ€CoV2 infection: 2 cases of typical Parsonageâ€Turner syndrome. European Journal of Neurology, 2022, , .	1.7	5
126	Singleâ€fiber studies for assigning pathogenicity of eight mitochondrial DNA variants associated with mitochondrial diseases. Human Mutation, 2020, 41, 1394-1406.	1.1	4

#	Article	IF	Citations
127	Assessing the upper motor neuron in amyotrophic lateral sclerosis using the triple stimulation technique: A multicenter prospective study. Clinical Neurophysiology, 2021, 132, 2551-2557.	0.7	4
128	A National French Consensus on Gene List for the Diagnosis of Charcotâ€“Marieâ€“Tooth Disease and Related Disorders Using Next-Generation Sequencing. Genes, 2022, 13, 318.	1.0	4
129	Ulnar neuropathy at the elbow: Reappraisal of the wrist-upper arm latency difference between ulnar and median nerves. Clinical Neurophysiology, 2020, 131, 372-376.	0.7	3
130	Comparison of MRI and motor evoked potential with triple stimulation technique for the detection of brachial plexus abnormalities in multifocal motor neuropathy. Muscle and Nerve, 2020, 61, 325-329.	1.0	3
131	Application of muscle ultrasound for the evaluation of patients with amyotrophic lateral sclerosis: An observational crossâ€sectional study. Muscle and Nerve, 2020, 62, 516-521.	1.0	3
132	A New Point Mutation in the PMP22 Gene in a Family Suffering From Atypical HNPP. Journal of Neuromuscular Diseases, 2020, 7, 505-510.	1.1	2
133	Type 1 FSHD with 6â€“10 Repeated Units: Factors Underlying Severity in Index Cases and Disease Penetrance in Their Relatives Attention. International Journal of Molecular Sciences, 2020, 21, 2221.	1.8	2
134	Visualization of Gray Matter Atrophy and Anterior Corticospinal Tract Signal Hyperintensity in Amyotrophic Lateral Sclerosis Using 7T MRI. Neurology, 2021, 96, 1094-1095.	1.5	2
135	An overview of motor unit number index reproducibility in amyotrophic lateral sclerosis. Iranian Journal of Neurology, 2019, 18, 119-126.	0.5	2
136	Refining NGS diagnosis of muscular disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 223-225.	0.9	1
137	Patient-reported impact of Charcot-Marie-Tooth disease: protocol for a real-world digital lifestyle study. Neurodegenerative Disease Management, 2021, 11, 21-33.	1.2	1
138	Multidisciplinary rehabilitation is relevant in severe myasthenia gravis: An observation. Annals of Physical and Rehabilitation Medicine, 2022, 65, 101593.	1.1	1
139	Neuropatie motorie multifocali con blocco della conduzione. EMC - Neurologia, 2017, 17, 1-7.	0.0	0